A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO
|
|||||
|
       
  |
 Comments are closed  Finance  biomedical, chemistry, clinical trials, equity, investment, IPO, Japan, life sciences, medical device, pharmaceuticals, physical sciences
Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, genomics, investment, IPO, life sciences, mathematics, medical device, pharmaceuticals, physical sciences
A biotechnology company developing treatments for disease and enhanced agricultural products with genome editing is raising $126 million in its initial public offering, or IPO, of common stock. . . . → Read More: Genome Editing Biotech Raises $126M in IPO Comments are closed Finance agriculture, biomedical, biotechnology, cancer, equity, genomics, investment, IPO, life sciences, pharmaceuticals 
CB Insights recently issued its annual Tech IPO Report, showing the number of initial public stock offerings in the technology industries unchanged from 2017. . . . → Read More: Infographic – Tech IPOs Flat in 2018
Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals
A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO Comments are closed Finance biomedical, biotechnology, computer science, engineering, equity, genomics, investment, IPO, life sciences, semiconductors
A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock. . . . → Read More: Cancer T-Cell Start-Up Gains $150 Million in IPO Comments are closed Finance biomedical, cancer, clinical trials, entrepreneurs, equity, Europe, investment, IPO, life sciences, pharmaceuticals, U.K., university A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering. . . . → Read More: Multi-Drug Resistance Antibiotic Developer to Issue IPO Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, pharmaceuticals A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering. . . . → Read More: Cancer Gene Therapy Company Raises $85M in IPO Comments are closed Finance biomedical, biotechnology, cancer, clinical trials, equity, investment, IPO, life sciences, pharmaceuticals, university A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million. . . . → Read More: Medical Robotics Company Crowdfunding IPO Comments are closed Finance biomedical, crowdfunding, engineering, equity, investment, IPO, licensing, life sciences, medical device, physical sciences, robotics, university |
||||
|
Copyright © 2020 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||